Clinical Trials Browser

Phase 2 × Recurrence × elotuzumab × Clear all

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05170789 2022-05-04

ESdRRMM

Phase 2 Withdrawn

Multiple Myeloma, Recurrence